Literature DB >> 8394451

Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain.

B D Cohen1, D J Goldstein, L Rutledge, W C Vass, D R Lowy, R Schlegel, J T Schiller.   

Abstract

The bovine papillomavirus E5 transforming protein appears to activate both the epidermal growth factor receptor (EGF-R) and the platelet-derived growth factor receptor (PDGF-R) by a ligand-independent mechanism. To further investigate the ability of E5 to activate receptors of different classes and to determine whether this stimulation occurs through the extracellular domain required for ligand activation, we constructed chimeric genes encoding PDGF-R and EGF-R by interchanging the extracellular, membrane, and cytoplasmic coding domains. Chimeras were transfected into NIH 3T3 and CHO(LR73) cells. All chimeras expressed stable protein which, upon addition of the appropriate ligand, could be activated as assayed by tyrosine autophosphorylation and biological transformation. Cotransfection of E5 with the wild-type and chimeric receptors resulted in the ligand-independent activation of receptors, provided that a receptor contained either the transmembrane domain of the PDGF-R or the cytoplasmic domain of the EGF-R. Chimeric receptors that contained both of these domains exhibited the highest level of E5-induced biochemical and biological stimulation. These results imply that E5 activates the PDGF-R and EGR-R by two distinct mechanisms, neither of which specifically involves the extracellular domain of the receptor. Consistent with the biochemical and biological activation data, coimmunoprecipitation studies demonstrated that E5 formed a complex with any chimera that contained a PDGF-R transmembrane domain or an EGF-R cytoplasmic domain, with those chimeras containing both domains demonstrating the greatest efficiency of complex formation. These results suggest that although different domains of the PDGF-R and EGF-R are required for E5 activation, both receptors are activated directly by formation of an E5-containing complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394451      PMCID: PMC237929     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  A glutamine residue in the membrane-associating domain of the bovine papillomavirus type 1 E5 oncoprotein mediates its binding to a transmembrane component of the vacuolar H(+)-ATPase.

Authors:  D J Goldstein; R Kulke; D Dimaio; R Schlegel
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

2.  The erythropoietin receptor transmembrane region is necessary for activation by the Friend spleen focus-forming virus gp55 glycoprotein.

Authors:  L I Zon; J F Moreau; J W Koo; B Mathey-Prevot; A D D'Andrea
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

3.  Stable association between the bovine papillomavirus E5 transforming protein and activated platelet-derived growth factor receptor in transformed mouse cells.

Authors:  L Petti; D DiMaio
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

4.  Analysis of the influences of the E5 transforming protein on kinetic parameters of epidermal growth factor binding and metabolism.

Authors:  C M Waters; K A Overholser; A Sorkin; G Carpenter
Journal:  J Cell Physiol       Date:  1992-08       Impact factor: 6.384

5.  Bovine papillomavirus E5 oncoprotein binds to the 16K component of vacuolar H(+)-ATPases.

Authors:  D J Goldstein; M E Finbow; T Andresson; P McLean; K Smith; V Bubb; R Schlegel
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

6.  A quantitative in vitro focus assay for bovine papilloma virus.

Authors:  I Dvoretzky; R Shober; S K Chattopadhyay; D R Lowy
Journal:  Virology       Date:  1980-06       Impact factor: 3.616

7.  Rous sarcoma virus transformed cells are resistant to cyclic AMP.

Authors:  C W Roth; T Singh; I Pastan; M M Gottesman
Journal:  J Cell Physiol       Date:  1982-04       Impact factor: 6.384

8.  The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand.

Authors:  F Lonardo; E Di Marco; C R King; J H Pierce; O Segatto; S A Aaronson; P P Di Fiore
Journal:  New Biol       Date:  1990-11

9.  Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor.

Authors:  D Pim; M Collins; L Banks
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  The BPV-1 E5 protein, the 16 kDa membrane pore-forming protein and the PDGF receptor exist in a complex that is dependent on hydrophobic transmembrane interactions.

Authors:  D J Goldstein; T Andresson; J J Sparkowski; R Schlegel
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

View more
  36 in total

1.  Artificial transmembrane oncoproteins smaller than the bovine papillomavirus E5 protein redefine sequence requirements for activation of the platelet-derived growth factor beta receptor.

Authors:  Kristina Talbert-Slagle; Sara Marlatt; Francisco N Barrera; Ekta Khurana; Joanne Oates; Mark Gerstein; Donald M Engelman; Ann M Dixon; Daniel Dimaio
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

2.  Bovine papillomavirus E5 protein induces oligomerization and trans-phosphorylation of the platelet-derived growth factor beta receptor.

Authors:  C C Lai; C Henningson; D DiMaio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Mutational analysis of the interaction between the bovine papillomavirus E5 transforming protein and the endogenous beta receptor for platelet-derived growth factor in mouse C127 cells.

Authors:  L A Nilson; R L Gottlieb; G W Polack; D DiMaio
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

Review 4.  Multiplicity of uses of monoclonal antibodies that define papillomavirus linear immunodominant epitopes.

Authors:  A B Jenson; M C Jenson; L Cowsert; S J Ghim; J P Sundberg
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

5.  Identification of amino acids in the transmembrane and juxtamembrane domains of the platelet-derived growth factor receptor required for productive interaction with the bovine papillomavirus E5 protein.

Authors:  L M Petti; V Reddy; S O Smith; D DiMaio
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 6.  The bovine papillomavirus E5 protein and the PDGF beta receptor: it takes two to tango.

Authors:  Kristina Talbert-Slagle; Daniel DiMaio
Journal:  Virology       Date:  2008-11-06       Impact factor: 3.616

7.  E5 oncoprotein transmembrane mutants dissociate fibroblast transforming activity from 16-kilodalton protein binding and platelet-derived growth factor receptor binding and phosphorylation.

Authors:  J Sparkowski; M Mense; J Anders; R Schlegel
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  The human T-cell leukemia/lymphotropic virus type 1 p12I proteins bind the interleukin-2 receptor beta and gammac chains and affects their expression on the cell surface.

Authors:  J C Mulloy; R W Crownley; J Fullen; W J Leonard; G Franchini
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

9.  The bovine papillomavirus type 1 E5 transforming protein specifically binds and activates the beta-type receptor for the platelet-derived growth factor but not other related tyrosine kinase-containing receptors to induce cellular transformation.

Authors:  D J Goldstein; W Li; L M Wang; M A Heidaran; S Aaronson; R Shinn; R Schlegel; J H Pierce
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Multiple transmembrane amino acid requirements suggest a highly specific interaction between the bovine papillomavirus E5 oncoprotein and the platelet-derived growth factor beta receptor.

Authors:  Valerie M Nappi; Lisa M Petti
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.